The Podocyte Problem: Understanding FSGS
Kirk Campbell, MD
Alessia Fornoni, MD, PhD
Optimizing Iron Deficiency Management in CKD: IV Iron Replacement Therapy Amid the Latest KDIGO Guidelines
Brendon Neuen, MBBS, PhD
Vous prescrivez uniquement des antihistaminiques pour traiter les patients atteints de Pa-MRC ? Il est temps de revoir votre approche !
Antoine Lanot, MD, PhD
Gil Yosipovitch, MD
Stuck on Antihistamines for Managing Patients With CKD-aP? Time to Reconsider!
Targeting CKD-aP at the Source: Key Mechanisms and Treatments
Steven Fishbane, MD
Maurizio Gallieni, MD
The Patient-Clinician Connection in Managing CKD-aP
James Burton, DM, FRCP
Lucio Manenti, MD, PhD
CKD-aP or Something Else? Decoding the Diagnosis
Emilio Sanchez, MD, PhD
Is CKD-aP Hiding in Your Dialysis Center?
CKD-aP: Beyond the Surface
Leonie Kraft, MD
Optimizing IgAN Care: Sparsentan’s Role Amid the Latest KDIGO Guideline Updates
Jürgen Floege, MD
Potassium Binders: Safety Comes First!
Ellie Kelepouris, MD, FACP, FAHA
Javed Butler, MD, MPH, MBA
Potassium Binders in Practice: Clinical Trial Evidence
Patrick Rossignol, MD, PhD
Optimizing RAASi/MRA Therapy in Patients with Heart Failure, CKD, and Hyperkalemia: A Microlearning Curriculum Approach
Javed Butler, MD
Implementing Potassium Binders: Practical Dosing and Long-Term Follow Up
Guidelines Update: RAASi/MRA Therapy in CKD and HF Management
Optimizing Hyperkalemia Management: Clinical Implications and Risk Assessment
Loading...
NEW FEATURES:
Tell us what you think by using our Feedback button
We're glad to see you're enjoying Global Kidney Academy… but how about a more personalized experience?
Press cancel to remain on Global Kidney Academy. Press the link below or the continue button to keep going.